Your session is about to expire
← Back to Search
BMS-986207 + Immunotherapy for Solid Cancers
Study Summary
This trial is testing an experimental medication, BMS-986207, to see if it is safe and effective when used alone or in combination with other existing medications to treat advanced solid cancers.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 1 Patients • NCT05005273Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My NSCLC has not been treated in its advanced or metastatic stage.My cancer has PD-L1 levels of 1% or higher, confirmed by a test within the last 3 months.I have serious heart problems that are not under control.I have an autoimmune disease.I am fully active or restricted in physically strenuous activity but can do light work.My cancer can be measured on scans and was checked within the last 28 days.I have another cancer that needs treatment at the same time.My cancer has spread to my brain but is under control.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many healthcare centers are conducting this experiment?
"This research is being conducted in multiple sites, such as the John Theurer Cancer Center at Hackensack University Medical Center (New jersey), University Health Network - Princess Margaret Cancer Centre (Toronto, Ontario) and a Local Institution based in Salt Lake City, Utah."
What is the current scope of this research's sample population?
"This medical trial necessitates the enrollment of 241 eligible participants. Patients located in John Theurer Cancer Center at Hackensack University Medical Center or University Health Network - Princess Margaret Cancer Centre can partake in this clinical study."
Are there any previous investigations that have utilized BMS-986207?
"BMS-986207 was initially tested in 2009 at the Texas Children's Hospital. Since then, a full 365 studies have been completed and 765 are actively recruiting participants - many of which are located in Hackensack, New jersey."
What ailments is BMS-986207 typically employed to remedy?
"BMS-986207 offers a promising treatment solution for anti-angiogenic therapy, malignant neoplasms, and unresectable melanoma."
Is enrollment currently open for this trial?
"The clinicaltrial.gov website shows that this research is actively seeking out participants; it was initially posted on November 30th, 2016 and most recently amended on November 1st, 2022."
Share this study with friends
Copy Link
Messenger